Seyed Rohollah Miri

Seyed Rohollah Miri


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2021 in Genes & Diseases
Verified
Journal Article
Open access
MZMohammad Reza Zinatizadeh
Mohammad Reza Zinatizadeh
BSBettina Schock
Bettina Schock
GGhanbar Mahmoodi Chalbatani
Ghanbar Mahmoodi Chalbatani
PZPeyman Kheirandish Zarandi
Peyman Kheirandish Zarandi
SJSeyed Amir Jalali
Seyed Amir Jalali
SMSeyed Rohollah Miri
Seyed Rohollah Miri
The nuclear factor kappa B (NF-kB) family of transcription factors plays an essential role as stressors in the cellular environment, and controls the expression of important regulatory genes such as immunity, inflammation, death, and cell proliferation. NF-kB protein is located in the cytoplasm, and can be activated by various cellular stimuli. There are two pathways for NF-kB activation, as the canonical and non-canonical pathways, which require complex molecular interactions with adapter proteins and phosphorylation and ubiquitinase enzymes. Accordingly, this increases NF-kB translocation in the nucleus and regulates gene expression. In this study, the concepts that emerge in different cellular systems allow the design of NF-kB function in humans. This would not only allow the development for rare diseases associated with NF-kB, but would also be used as a source of useful information to eliminate widespread consequences such as cancer or inflammatory/immune diseases.

1 May 2019 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
GGhanbar Mahmoodi Chalbatani
Ghanbar Mahmoodi Chalbatani
HDHassan Dana
Hassan Dana
EGElahe Gharagouzloo
Elahe Gharagouzloo
SGSantiago Grijalvo
Santiago Grijalvo
Ramon EritjaRamon Eritja
Ramon Eritja
VMVahid Marmari
Vahid Marmari
Cancer is one of the most complex diseases that has resulted in multiple genetic disorders and cellular abnormalities. Globally, cancer is the most common health concern disease that is affecting human beings. Great efforts have been made over the past decades in biology with the aim of searching novel and more efficient tools in therapy. Thus, small interfering RNAs (siRNAs) have been considered one of the most noteworthy developments which are able to regulate gene expression following a process known as RNA interference (RNAi). RNAi is a post-transcriptional mechanism that involves the inhibition of gene expression through promoting cleavage on a specific area of a target messenger RNA (mRNA). This technology has shown promising therapeutic results for a good number of diseases, especially in cancer. However, siRNA therapeutics have to face important drawbacks in therapy including stability and successful siRNA delivery in vivo. In this regard, the development of effective siRNA delivery systems has helped addressing these issues by opening novel therapeutic windows which have allowed to build up important advances in Nanomedicine. In this review, we discuss the progress of siRNA therapy as well as its medical application via nanoparticle-mediated delivery for cancer treatment.

1 January 2019 in Practical Laboratory Medicine
Verified
Journal Article
Open access
GGhanbar Mahmoodi Chalbatani
Ghanbar Mahmoodi Chalbatani
HDHassan Dana
Hassan Dana
FMFeridon Memari
Feridon Memari
EGElahe Gharagozlou
Elahe Gharagozlou
SAShirin Ashjaei
Shirin Ashjaei
FRFatemeh Nouri Rouzbahani
Fatemeh Nouri Rouzbahani
Cancer is the second leading cause of death globally. piRNAs, which are a novel type of identified small noncoding RNA (ncRNA), play a crucial role in cancer genomics. In recent years, a relatively large number of studies have demonstrated that several piRNA are aberrantly expressed in various kinds of cancers including gastric cancer, bladder cancer, breast cancer, colorectal cancer and Lung cancer and may probably serve as a novel therapeutic target and biomarker for cancer treatment. The present review summarized current advances in our knowledge of the roles of piRNAs in cancer.

2 February 2023 in Diagnostics
Verified
Journal Article
Open access
PDF file
ZAZeinab Mohseni Afshar
Zeinab Mohseni Afshar
APAli Tavakoli Pirzaman
Ali Tavakoli Pirzaman
BKBardia Karim
Bardia Karim
SAShiva Rahimipour Anaraki
Shiva Rahimipour Anaraki
RHRezvan Hosseinzadeh
Rezvan Hosseinzadeh
Soheil EbrahimpourSoheil Ebrahimpour
Soheil Ebrahimpour
Since the beginning of the coronavirus disease 2019 (COVID-19) pandemic, there have been multiple peaks of the SARS-CoV-2 (severe acute respiratory syndrome coronavirus virus 2) infection, mainly due to the emergence of new variants, each with a new set of mutations in the viral genome, which have led to changes in the pathogenicity, transmissibility, and morbidity. The Omicron variant is the most recent variant of concern (VOC) to emerge and was recognized by the World Health Organization (WHO) on 26 November 2021. The Omicron lineage is phylogenetically distinct from earlier variants, including the previously dominant Delta SARS-CoV-2 variant. The reverse transcription–polymerase chain reaction (RT–PCR) test, rapid antigen assays, and chest computed tomography (CT) scans can help diagnose the Omicron variant. Furthermore, many agents are expected to have therapeutic benefits for those infected with the Omicron variant, including TriSb92, molnupiravir, nirmatrelvir, and their combination, corticosteroids, and interleukin-6 (IL-6) receptor blockers. Despite being milder than previous variants, the Omicron variant threatens many lives, particularly among the unvaccinated, due to its higher transmissibility, pathogenicity, and infectivity. Mounting evidence has reported the most common clinical manifestations of the Omicron variant to be fever, runny nose, sore throat, severe headache, and fatigue. This review summarizes the essential features of the Omicron variant, including its history, genome, transmissibility, clinical manifestations, diagnosis, management, and the effectiveness of existing vaccines against this VOC.

1 June 2021 in Annals of Medicine & Surgery
Verified
Journal Article
Open access
AGAta Garajei
Ata Garajei
AKAli A. Kheradmand
Ali A. Kheradmand
SMSeyed Rohollah Miri
Seyed Rohollah Miri
AEAzadeh Emami
Azadeh Emami
To assess the availability, success rate and complications of microvascular iliac crest free flap for reconstruction of mandibular segmental defects. In this retrospective-descriptive study, we report patients who had undergone segmental mandibular resection for pathologic lesions and received reconstruction with iliac crest microvascular free flap between 2016 and 2019. Clinical and demographic data of all the cases were collected. Success was regarded as complete consolidation of the bone graft in panoramic radiograph. Postoperative complications were defined as major or minor based on the need for intervention. T-test, Kolomogorov_Smirnov, and multivariate analysis were used and the p-value<0.05 was considered to be statistically significant. Of all 30 patients, 16 were women and 14 were men with an average age of 27.2 years (range 14–40). Patients were followed for 12–60 month (mean: 38.4). One flap was lost due to unsalvageable venous thrombosis. Six other cases had post-op complications while smoking and diabetes were associated with more complications (P = 0.036). Twenty-three patients received primary reconstruction which was more successful than secondary ones (P = 0.003). Osteogenic sarcoma was associated with greater risk of complications (P < 0.01). The results of this study suggest that iliac crest microvascular free flap serves as a promising option for the reconstruction of mandibular defects, providing excellent contour and acceptable success rate with low donor site morbidity. Future studies will focus on the role of systemic diseases in post-op complications and flap failures.

1 July 2021 in Saudi Journal of Biological Sciences
Verified
Journal Article
Open access
GCGhanbar Mahmoodi Chalbatani
Ghanbar Mahmoodi Chalbatani
EGElahe Gharagouzloo
Elahe Gharagouzloo
FMFereidoon Memari
Fereidoon Memari
HDHassan Dana
Hassan Dana
MHMohammad Hosein Mohammadi Hadloo
Mohammad Hosein Mohammadi Hadloo
HMHabibollah Mahmoodzadeh
Habibollah Mahmoodzadeh
Circular RNAs (circRNAs) are a new kind of non-coding RNA(ncRNA). Throughout research, we see an increase in the number of studies demonstrating that circRNAs occupy a pivotal role in the growth and advancement of human tumors. Nevertheless, hsa_circ_001787′s role in the evolution of colorectal cancer (CRC) remains unclear. This current study ascertained the expression level of circRNA001787 in CRC specimens and neighboring healthy tissues, and investigated the miRNAs associate with hsa_circ_001787, as well as the relationship between hsa_circ_001787 and pathological factors. First, the expression level of hsa_circ_001787 was measured in 43 matched Tissues from CRC and normal tissues through using real-time quantitative reverse transcription PCR (qRT-PCR). Second, based on circular RNA-microRNA and microRNA-mRNA pairs, a circRNA-miRNA-mRNA network was created. The survival rate of mRNAs was investigated through the GEPIA in the network. Regarding the elucidated function analysis of hsa_circ_001787, The biological, molecular, cellular function (GO) and pathway (KEGG) enrichment was obtained. We detected that hsa_circ_001787 expression level was significantly down expressed in CRC tissue versus paired CRC histological normal tissue. The area under the curve (AUC) was 0.83. The expression level of hsa_circ_001787 was significantly associated with pathological factors such as tumor grade and the primary site of the tumor. Based on the hsa_circ_001787, a novel circRNA/miRNA/mRNA network has been built up, four miRNAs, and 24 mRNA. The pathway of mRNAs analyzed in the pathogenesis of CRC. Four genes distinguished via the GEPIA database were positively linked to the overall survival of CRC patients. Our study suggested that hsa_circ_001787 was significantly down-regulated in CRC. We might be able to use this as a new biomarker in the screening of CRC. Furthermore, our finding achieves a broader understanding of the regulatory mechanisms by which hsa_circ_001787 acts as ceRNA in colorectal cancer.